public_health

New York – November 05, 2026 -- The Vaccine Guidance Review Panel, a multi-society effort of four U.S. medical organizations, has endorsed influenza, RSV and COVID-19 vaccination recommendations for adults and children. The guidance is aligned with Advisory Committee on Immunization Practices (ACIP) recommendations issued before June 2025.

Panel draws on four specialty societies and four guidance issuers

Experts from the American Academy of Allergy, Asthma & Immunology (AAAAI), the American Thoracic Society (ATS), the American College of Chest Physicians (CHEST) and the Society of Critical Care Medicine (SCCM) reviewed the vaccination-development process. They unanimously endorsed it, together with the resulting guidance from the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG) and the Infectious Diseases Society of America (IDSA).

Philadelphia – November 05, 2026 -- The share of US newborns not receiving the routine intramuscular vitamin K injection more than doubled between 2017 and 2025, rising from 3.1% to 6.8%, according to a Children's Hospital of Philadelphia (CHOP) study published in JAMA. It is the largest retrospective analysis of the trend to date, covering more than 5.2 million hospital births.

Infants without the injection showed a 47% higher risk of bleeding

Researchers analyzed deidentified electronic health record data from hospitals and clinics in all 50 states and Washington, D.C. The cohort included infants born at 35 to 43 weeks' gestation and followed them through their first six months of life. Of these, 234,825 infants (4.5%) did not receive intramuscular vitamin K at birth.

Bielefeld – November 04, 2026 -- Germany's federal research ministry is funding a sub-study worth roughly €2 million to test whether regular forest play changes children's risk of allergies, asthma and ADHD. The trial sits inside a long-term cohort of about 1,000 newborns in the East Westphalia-Lippe region.

The parent project, "Kleine Eulen OWL", is run by a research team at Evangelisches Klinikum Bethel (EvKB) at University Hospital OWL. The source describes it as unique nationwide. It follows the children into adulthood to map how the microbiome develops and how early living conditions affect later disease risk. Over the first six years of life, researchers analyze the influence of genes, pregnancy and birth, stress, environment, family, pets, lifestyle and medication on the microbiome.

PRETORIA – November 05, 2026 -- NTL HEALTHCARE proposed local clinical validation and hospital pilots in South Africa for CerviCARE AI, an on-device cervical screening tool that works offline and analyzes images in approximately five seconds.

NTL cites 98% sensitivity for high-grade lesions in a 2024 study

Executive Vice President Dr. Jake Byun presented the solution at the 2026 Korea-South Africa Future Dialogue, co-hosted by the Korean Embassy and the Korea-Africa Foundation. He said NTL's cervical screening expertise dates to 1996 and covers more than eight million cases. A 2024 Scientific Reports study reported 98% sensitivity for high-grade lesions.

Byun said CerviCARE AI could support assessment, referral, treatment and follow-up after positive HPV results. It would not replace HPV testing or clinical judgment.

SUNNYVALE – – November 03, 2026 -- Cepheid, a Danaher operating company, has received U.S. Food and Drug Administration clearance for the Xpert Hemorrhagic Fever Panel, a multiplex PCR test that detects four hemorrhagic fever virus groups from a single sample in approximately 61 minutes.

Single cartridge covers Ebola, Marburg, Lassa and CCHF

The panel gives qualitative detection and identification of RNA from Ebola virus, Marburg virus, Lassa virus and Crimean-Congo hemorrhagic fever (CCHF) virus. The Ebola target covers the Zaire, Sudan, Taï Forest and Bundibugyo species, which the test does not differentiate.

The test runs on Cepheid's GeneXpert Dx systems. Its closed-cartridge design limits cross-contamination between samples, and sample processing includes viral inactivation to support safe laboratory workflows.

CHICAGO – October 30, 2026 -- The American Lung Association Research Institute has invested $21 million in research and related scientific activities this year, bringing its total direct research funding over the past decade to $193 million.

More than $11 million goes to 120 research projects

The $21 million covers direct research funding of more than $11 million for 120 projects, plus related scientific activities. The projects run through three programs: the Awards and Grants Program, the Airways Clinical Research Centers Network and the Accelerator Program. The $193 million ten-year figure also includes the infrastructure and scientific support needed to advance research.

BOSTON – October 30, 2026 -- Nearly 150 million Americans now live in areas with unhealthy air quality, according to a new issue brief from nonprofit consultancy FSG that urges funders and policymakers to back community-led respiratory health programs.

The brief, titled "Improving Community Respiratory Health: Place-Based Lessons from the Field," was released in recognition of Lung Health Day. It draws on research and interviews with leaders from community-based organizations, philanthropy, healthcare and advocacy groups.

Six elements define effective place-based respiratory models

FSG identifies six common characteristics of successful models:

TOKYO – October 29, 2026 -- The Global Health Innovative Technology (GHIT) Fund has committed about JPY 1.06 billion (USD 6.8 million) to nine R&D projects covering drugs, vaccines and diagnostics for malaria, neglected tropical diseases (NTDs) and emerging infectious diseases such as Ebola.

Trachoma rapid test receives JPY 450 million for clinical validation and launch

The largest single award, about JPY 450 million (USD 2.9 million), goes to a point-of-care rapid diagnostic test for trachoma. The project is led by Drugs and Diagnostics for Tropical Diseases, Medical & Biological Laboratories (MBL), The Carter Center and Big Eye Diagnostics, and has received GHIT support since 2024.

United States – October 29, 2026 -- Influenza-associated hospitalizations reached 3.5 per 1,000 hospitalizations in the week beginning September 21, 2026, nearly three times the next-highest rate recorded at the same point in the prior six flu seasons, according to a Truveta Data analysis.

Hospitalization rate climbs more than 2.5 times faster than in any prior season

From the week beginning August 31 through the week beginning September 21, the rate rose by an average of 0.7 hospitalizations per 1,000 each week. The next-fastest increase over the comparable period was 0.3 per 1,000 per week, in 2022–23.

Across the six prior seasons, the median weekly change at this point was −0.03 per 1,000. Hospitalization rates were generally stable or declining at this stage of past seasons.

United States – October 29, 2026 -- The rate of e-bike-related emergency department (ED) visits rose 760.2% between January–August 2023 and January–August 2026, while traditional bicycle visits increased only 7.9%, according to a Truveta Data analysis.

E-bike visits climbed from 1.2 to 10.1 per 100,000 people with an ED visit. The traditional bicycle rate moved from 59.4 to 64.1 per 100,000. Traditional bicycles still dominate in absolute volume: the study period recorded 63,811 traditional bicycle ED visits against 4,769 for e-bikes.

Pediatric e-bike ED visit rate rises 19.1-fold to 35.7 per 100,000

Patients aged 0–17 saw the steepest increase, from 1.9 to 35.7 per 100,000, against a 1.5-fold rise for traditional bicycles in the same group. E-bike rates also grew 7.7-fold among 18–24-year-olds, 7.4-fold among 25–44-year-olds, 7.6-fold among 45–64-year-olds and 3.2-fold among those 65 and older.